论文部分内容阅读
表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)不良反应以皮疹、腹泻为主,吉非替尼(易瑞沙)和厄洛替尼分别于2005年和2007年在中国上市并获得了良好的疗效,但是仍然有部分可能获益的患者因不良反应而不能接受EGFR-TKI的治疗。盐酸埃克替尼(凯美纳)是我国研制的、具有完全自主知识产权的、高效特异性EGFR-TKI。本病例服用吉非替尼后出现Ⅲ～Ⅳ度腹泻,应用止泻药无效,患者因无法耐受停药。患者改用盐酸埃克替尼口服至今共7个月,未见明显不良反应,用药后1个月疗效评估:病情稳定(SD),体能状况、生活质量得到改善。说明盐酸埃克替尼治疗晚期非小细胞肺癌(NSCLC)具有较好的有效性、安全性和耐受性,与吉非替尼、厄洛替尼相比,疗效较优且不良反应较少。
Adverse reactions to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) were mainly rash and diarrhea. Gefitinib (iressa) and erlotinib were listed in China in 2005 and 2007 respectively However, there are still some patients who may benefit from the adverse reactions can not receive EGFR-TKI treatment. Icotinib hydrochloride (Kemer) is developed in China, with completely independent intellectual property rights, highly specific EGFR-TKI. The case of gefitinib after Ⅲ ~ Ⅳ degree of diarrhea, the application of antidiarrheal invalid, patients can not tolerate withdrawal. Patients switched to oral Icutinib hydrochloride for a total of 7 months, no significant adverse reactions, 1 month after treatment efficacy evaluation: stable disease (SD), physical fitness, quality of life improved. The results showed that the efficacy, safety and tolerability of imatinib hydrochloride in the treatment of advanced non-small cell lung cancer (NSCLC) were better than gefitinib and erlotinib, with less adverse reactions .